Imaging inflammation and its resolution in health and disease: current status, clinical needs, challenges, and opportunities
- PMID: 31577913
- PMCID: PMC6894066
- DOI: 10.1096/fj.201902024
Imaging inflammation and its resolution in health and disease: current status, clinical needs, challenges, and opportunities
Abstract
Inflammation is a normal process in our body; acute inflammation acts to suppress infections and support wound healing. Chronic inflammation likely leads to a wide range of diseases, including cancer. Tools to locate and monitor inflammation are critical for developing effective interventions to arrest inflammation and promote its resolution. To identify current clinical needs, challenges, and opportunities in advancing imaging-based evaluations of inflammatory status in patients, the U.S. National Institutes of Health convened a workshop on imaging inflammation and its resolution in health and disease. Clinical speakers described their needs for image-based capabilities that could help determine the extent of inflammatory conditions in patients to guide treatment planning and undertake necessary interventions. The imaging speakers showcased the state-of-the-art in vivo imaging techniques for detecting inflammation in different disease areas. Many imaging capabilities developed for 1 organ or disease can be adapted for other diseases and organs, whereas some have promise for clinical utility within the next 5-10 yr. Several speakers demonstrated that multimodal imaging measurements integrated with serum-based measures could improve in robustness for clinical utility. All speakers agreed that multiple inflammatory measures should be acquired longitudinally to comprehend the dynamics of unresolved inflammation that leads to disease development. They also agreed that the best strategies for accelerating clinical translation of imaging inflammation capabilities are through integration between new imaging techniques and biofluid-based biomarkers of inflammation as well as already established imaging measurements.-Liu, C. H., Abrams, N. D., Carrick, D. M., Chander, P., Dwyer, J., Hamlet, M. R. J., Kindzelski, A. L., PrabhuDas, M., Tsai, S.-Y. A., Vedamony, M. M., Wang, C., Tandon, P. Imaging inflammation and its resolution in health and disease: current status, clinical needs, challenges, and opportunities.
Keywords: chronic inflammation; clinical translation; in vivo; inflammatory status; molecular imaging.
Conflict of interest statement
The authors thank the speakers (listed below) for participating in multiple preworkshop discussions and conference calls and for providing their insights on the clinical needs, current state-of-the-art imaging techniques, as well as challenges, opportunities, and recommendations associated with the image-based evaluation of inflammation and its resolution processes. The authors greatly appreciate their time and thoughtful input in reviewing the manuscript. Speakers: Charles Serhan (Brigham and Women’s Hospital, Boston, MA, USA); Michael Postow and Kayvan R. Keshari (Memorial Sloan Kettering Cancer Center, New York, NY, USA); James R. Hebert (University of South Carolina, Columbia, SC, USA); Rohit Loomba (University of California–San Diego, La Jolla, CA, USA); Fedor Lurie (Jobst Vascular Institute, Toledo, OH, USA); Ru-Rong Ji (Duke University, Durham, NC, USA); Victoria Chiou (U.S. FDA, Silver Spring MD, USA); Yaron Rotman and Ahmed Gharib, (National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA); Stefan Uderhardt (National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA); Xueding Wang (University of Michigan, Ann Arbor, MI, USA); Alexei Bogdanov (University of Massachusetts, Worcester, MA, USA); Irene Georgakoudi (Tufts University, Medford, MA, USA); Amy Leblanc (National Cancer Institute, NIH, Bethesda, MD, USA); Stephanie Cush [Foundation for the NIH (FNIH), Bethesda, MD, USA]; Martin G. Pomper (Johns Hopkins Medical School, Baltimore, MD, USA); Laura Beretta (University of Texas M. D. Anderson Cancer Center, Houston, TX, USA); Zahi Fayad (Icahn School of Medicine at Mount Sinai, New York, NY, USA); Eva M. Ratai (Massachusetts General Hospital, Boston, MA, USA); Milind Y. Desai (Cleveland Clinic, Cleveland, OH, USA) Sandip Biswal (Stanford University, Stanford, CA, USA). The authors declare no conflicts of interest.
Figures
Similar articles
-
Metabolic Regulation of Inflammation and Its Resolution: Current Status, Clinical Needs, Challenges, and Opportunities.J Immunol. 2021 Dec 1;207(11):2625-2630. doi: 10.4049/jimmunol.2100829. J Immunol. 2021. PMID: 34810268 Free PMC article. Review.
-
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.J Hepatol. 2020 Mar;72(3):401-410. doi: 10.1016/j.jhep.2019.09.018. Epub 2019 Oct 4. J Hepatol. 2020. PMID: 31589891 Clinical Trial.
-
Targeted Molecular Imaging of Cardiovascular Diseases by Iron Oxide Nanoparticles.Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):601-613. doi: 10.1161/ATVBAHA.120.315404. Epub 2020 Dec 24. Arterioscler Thromb Vasc Biol. 2021. PMID: 33356385 Review.
-
PET/MR Imaging in Vascular Disease: Atherosclerosis and Inflammation.PET Clin. 2016 Oct;11(4):479-88. doi: 10.1016/j.cpet.2016.05.009. Epub 2016 Jul 27. PET Clin. 2016. PMID: 27593251 Review.
-
Atherosclerosis Immunoimaging by Positron Emission Tomography.Arterioscler Thromb Vasc Biol. 2020 Apr;40(4):865-873. doi: 10.1161/ATVBAHA.119.313455. Epub 2020 Feb 6. Arterioscler Thromb Vasc Biol. 2020. PMID: 32078338 Free PMC article. Review.
Cited by
-
Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities.Radiol Imaging Cancer. 2021 May;3(3):e200052. doi: 10.1148/rycan.2021200052. Radiol Imaging Cancer. 2021. PMID: 34047667 Free PMC article. Review.
-
Indole-Based and Cyclopentenylindole-Based Analogues Containing Fluorine Group as Potential 18F-Labeled Positron Emission Tomography (PET) G-Protein Coupled Receptor 44 (GPR44) Tracers.Pharmaceuticals (Basel). 2023 Aug 24;16(9):1203. doi: 10.3390/ph16091203. Pharmaceuticals (Basel). 2023. PMID: 37765011 Free PMC article. Review.
-
Inflammation and cancer: paradoxical roles in tumorigenesis and implications in immunotherapies.Genes Dis. 2021 Oct 18;10(1):151-164. doi: 10.1016/j.gendis.2021.09.006. eCollection 2023 Jan. Genes Dis. 2021. PMID: 37013041 Free PMC article. Review.
-
Monitoring and Prognostic Analysis of Severe Cerebrovascular Diseases Based on Multi-Scale Dynamic Brain Imaging.Front Neurosci. 2021 Jun 30;15:684469. doi: 10.3389/fnins.2021.684469. eCollection 2021. Front Neurosci. 2021. PMID: 34276294 Free PMC article.
-
Molecular Insights Into Lysyl Oxidases in Cartilage Regeneration and Rejuvenation.Front Bioeng Biotechnol. 2020 Apr 30;8:359. doi: 10.3389/fbioe.2020.00359. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 32426343 Free PMC article. Review.
References
-
- Hodi F. S., Chiarion-Sileni V., Gonzalez R., Grob J. J., Rutkowski P., Cowey C. L., Lao C. D., Schadendorf D., Wagstaff J., Dummer R., Ferrucci P. F., Smylie M., Hill A., Hogg D., Marquez-Rodas I., Jiang J., Rizzo J., Larkin J., Wolchok J. D. (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 19, 1480–1492 - PubMed
-
- Wolchok J. D., Rollin L., Larkin J. (2017) Nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 2503–2504; erratum: 379, 2185 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources